Specialty Pharmacy

Specialty pharmacies have multiple decisions to make for clinical programs that accompany a contract with a manufacturer.

FDA extends biologics license application review for MS drug ocrelizumab (Ocrevus) to allow for more information on manufacturing process.

Niraparib is an investigational PARP inhibitor currently being evaluated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers.

Metastasis affects as many as 5% of cancer patients around the world.

Top news of the day from across the health care landscape.

The FDA granted orphan drug designation to nintedanib, a triple angiokinase inhibitor, for the treatment of mesothelioma.

Syringe services programs seek to halt the spread of HIV among injection drug users.

After 2 years of exclusion, Harvoni has been added to the Express Scripts national formulary for the treatment of hepatitis C.

Cyclin-dependent kinase inhibitor reduces Ki67 expression and shows promise in breast cancer treatment.

Top news of the day from across the health care landscape.

When treatment with DMARDs does not work, biologic agents are used to treat RA.

Lack of adherence to HIV medications can create resistance since the virus mutates quickly.

Risankizumab achieved higher rates of clinical response in patients with Crohn’s disease.

Pennsylvania health department recommends that patients be screened for HIV, and hepatitis B and C viruses.

FDA grants accelerated approval for rucaparib (Rubraca) to treat advanced ovarian cancer.

Pembrolizumab was associated with clinically meaningful improvements in quality of life over chemotherapy.

Anti-inflammatory drugs suppress PGE2 production and leads to adverse events from peripheral blood hematopoietic stem cell harvesting.

Integrase inhibitors can reduce the HIV viral load to decrease transmission of the disease.

Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses how specialty stakeholders can take steps to improve the perception surrounding specialty pharmacies following recent drug cost controversies.

Top news of the day from across the health care landscape.

ICER seeks comment on the effectiveness and value of disease modifying therapies for relapsing remitting and primary progressive multiple sclerosis.

Global HIV incidence rates drop in some African countries.

Top news of the week in oncology and cancer drug development.

Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.

Jury declares Merck’s acquired HCV drug patent valid.

The biosimilar epoetin was well-tolerated in elderly cancer patient populations.

FDA-approved drug could reduce the risk of death in adults with diabetes and cardiovascular disease.

Top news of the day from across the health care landscape.